FR14C0069I2 - Composition pharmaceutique comprenant le lurasidone - Google Patents

Composition pharmaceutique comprenant le lurasidone

Info

Publication number: FR14C0069I2
Authority: FR; France
Prior art keywords: lurasidone; pharmaceutical composition; pharmaceutical; composition
Prior art date: 2005-05-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR14C0069C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sumitomo Pharma Co Ltd

Original Assignee

Sumitomo Dainippon Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-26

Filing date

2014-09-16

Publication date

2015-11-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0069(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-16 Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd

2014-10-24 Publication of FR14C0069I1 publication Critical patent/FR14C0069I1/fr

2015-11-20 Application granted granted Critical

2015-11-20 Publication of FR14C0069I2 publication Critical patent/FR14C0069I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Inorganic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Neurosurgery (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FR14C0069C 2005-05-26 2014-09-16 Composition pharmaceutique comprenant le lurasidone Active FR14C0069I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2005153508		2005-05-26
PCT/JP2006/310571 WO2006126681A1 (fr)	2005-05-26	2006-05-26	Composition pharmaceutique

Publications (2)

Publication Number	Publication Date
FR14C0069I1 FR14C0069I1 (fr)	2014-10-24
FR14C0069I2 true FR14C0069I2 (fr)	2015-11-20

Family

ID=37452103

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR14C0069C Active FR14C0069I2 (fr)	2005-05-26	2014-09-16	Composition pharmaceutique comprenant le lurasidone

Country Status (22)

Country	Link
US (5)	US8729085B2 (fr)
EP (2)	EP1884242B1 (fr)
JP (2)	JP4733120B2 (fr)
KR (2)	KR101380088B1 (fr)
CN (2)	CN102048734B (fr)
AU (1)	AU2006250340C1 (fr)
BR (2)	BR122020005056B1 (fr)
CA (1)	CA2606510C (fr)
CY (2)	CY1114118T1 (fr)
DK (2)	DK2422783T3 (fr)
ES (2)	ES2535478T3 (fr)
FR (1)	FR14C0069I2 (fr)
HK (1)	HK1108379A1 (fr)
HU (1)	HUS1400051I1 (fr)
LU (1)	LU92550I2 (fr)
MX (1)	MX2007014872A (fr)
NL (1)	NL300690I2 (fr)
PL (1)	PL1884242T3 (fr)
PT (1)	PT1884242E (fr)
RU (1)	RU2398586C3 (fr)
SI (1)	SI1884242T1 (fr)
WO (1)	WO2006126681A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8980316B2 (en)	2005-05-18	2015-03-17	Sumitomo Dainippon Pharma Co., Ltd.	Stable tablet containing droxidopa
KR101380088B1 (ko)	2005-05-26	2014-04-10	다이닛본 스미토모 세이야꾸 가부시끼가이샤	약학 조성물
CN101945657B (zh) *	2008-02-11	2015-04-22	大日本住友制药株式会社	具有改善的溶出性的片剂
CN102119034B (zh)	2008-06-13	2013-05-22	大日本住友制药株式会社	在口腔中快速崩解的片剂和制备其的方法
JP5694773B2 (ja) *	2008-09-30	2015-04-01	テバ製薬株式会社	圧縮成型製剤およびその製造方法
CN105640918A (zh)	2009-05-19	2016-06-08	细胞基因公司	4-氨基-2-(2,6-二氧代哌啶-3-基)异吲哚啉-1,3-二酮的制剂
CN103249416B (zh)	2010-10-18	2019-06-04	大日本住友制药株式会社	注射用缓释制剂
WO2012063246A1 (fr) *	2010-11-11	2012-05-18	Mapi Pharma Ltd.	Forme amorphe du chlorhydrate de lurasidone
WO2012107890A2 (fr) *	2011-02-10	2012-08-16	Ranbaxy Laboratories Limited	Formes cristallines de chlorhydrate de lurasidone
WO2012156981A1 (fr)	2011-05-13	2012-11-22	Cadila Healthcare Limited	Compositions pharmaceutiques de lurasidone
WO2013014665A1 (fr)	2011-07-28	2013-01-31	Mapi Pharma Ltd.	Composés intermédiaires et procédé pour la préparation de lurasidone et de sels de celle-ci
CN102911169B (zh) *	2011-08-02	2015-05-06	上海医药工业研究院	一种卢拉西酮的制备方法
US20140243383A1 (en)	2011-08-24	2014-08-28	Cadila Healthcare Limited	Pharmaceutical compositions of silodosin
CN103446071B (zh) *	2012-05-29	2017-12-19	江苏豪森药业集团有限公司	一种口服片剂及其制备方法和用途
CN102688210A (zh) *	2012-06-21	2012-09-26	李兴惠	鲁拉西酮的药物组合物和制备方法
CN102688209A (zh) *	2012-06-21	2012-09-26	李兴惠	鲁拉西酮片和制备方法
CN103536568B (zh) *	2012-07-12	2016-12-07	成都康弘药业集团股份有限公司	一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) *	2012-12-06	2015-02-18	江苏先声药物研究有限公司	一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) *	2013-12-11	2015-06-11	Saravanan Kannusamy	Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (fr)	2014-07-25	2016-01-28	Lupin Limited	Composition pharmaceutique orale de lurasidone
CN104606133A (zh) *	2015-01-07	2015-05-13	万特制药(海南)有限公司	鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (fr) *	2015-03-05	2016-09-09	Jubilant Generics Limited	Compositions pharmaceutiques de lurasidone et son procédé de préparation
DE102016205950A1 (de) *	2016-04-08	2017-10-12	Dietrich Seidel	Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
WO2018083117A1 (fr) *	2016-11-02	2018-05-11	Sanovel Ilac Sanayi Ve Ticaret A.S.	Compositions pharmaceutiques orales solides de chlorhydrate de lurasidone
CN108567758A (zh) *	2017-03-08	2018-09-25	湖南洞庭药业股份有限公司	盐酸鲁拉西酮片剂及其制备方法
CN107854445A (zh) *	2017-12-17	2018-03-30	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮分散片及其制备方法
CN107875122A (zh) *	2017-12-17	2018-04-06	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854446A (zh) *	2017-12-19	2018-03-30	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮口崩片及其制备方法
SG11202008233WA (en)	2018-02-28	2020-09-29	Sumitomo Dainippon Pharma Co Ltd	Aqueous suspension pharmaceutical preparation with controlled dissolution
EP3772992B1 (fr)	2018-04-10	2022-05-18	Freshfoodz GmbH	Procédé de conservation d'un plat à préparer chaud et de préparation d'aliments pour collectivité
CN115843243A (zh) *	2020-08-26	2023-03-24	浙江华海药业股份有限公司	盐酸鲁拉西酮组合物及其制备方法
AT17300U3 (de) *	2020-12-03	2022-02-15	G L Pharma Gmbh	Feste orale pharmazeutische Zusammensetzung
JPWO2022138717A1 (fr) *	2020-12-23	2022-06-30

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4600579A (en) *	1983-06-07	1986-07-15	Mallinckrodt, Inc.	N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en)	1984-04-23	1985-11-05	National Starch And Chemical Corporation	Compressible starches as binders for tablets or capsules
US4609675A (en)	1984-08-17	1986-09-02	The Upjohn Company	Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en)	1987-09-17	1989-06-06	Mallinckrodt, Inc.	Compositions containing ibuprofen
US5047246A (en)	1988-09-09	1991-09-10	Bristol-Myers Company	Direct compression cyclophosphamide tablet
US4911921A (en)	1989-02-02	1990-03-27	Mallinckrodt, Inc.	High ibuprofen content granulations
US5104648A (en)	1989-02-02	1992-04-14	Mallinckrodt Specialty Chemicals Company	High ibuprofen content granulations
JP2800953B2 (ja)	1990-07-06	1998-09-21	住友製薬株式会社	新規なイミド誘導体
US5605889A (en)	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
ES2181868T3 (es)	1995-02-28	2003-03-01	Aventis Pharma Inc	Composicion farmaceutica para compuestos de piperidinoalcanol.
JP4022269B2 (ja) *	1995-05-26	2007-12-12	協和醗酵工業株式会社	医薬組成物
PT1033132E (pt)	1997-10-20	2005-09-30	Dainippon Pharmaceutical Co	Composicao de farmaco rapidamente soluvel
JP4063386B2 (ja) *	1998-01-29	2008-03-19	キッセイ薬品工業株式会社	速放性経口医薬品組成物
US6150366A (en)	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations
MX339071B (es) *	1999-03-31	2016-05-09	Janssen Pharmaceutica Nv	Almidon pregelatinizado en una formulacion de liberacion controlada.
US6586617B1 (en)	1999-04-28	2003-07-01	Sumitomo Chemical Takeda Agro Company, Limited	Sulfonamide derivatives
AU2001246861A1 (en) *	2000-04-10	2001-10-23	Sumitomo Pharmaceuticals Co. Ltd.	Sustained release preparations
JP4868695B2 (ja) *	2000-09-22	2012-02-01	大日本住友製薬株式会社	崩壊性が良好な経口製剤
JP4250423B2 (ja)	2001-03-19	2009-04-08	大日本住友製薬株式会社	アリール置換脂環式化合物及びそれを含有する医薬組成物
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
EP1944030B1 (fr) *	2002-08-22	2018-08-01	Sumitomo Dainippon Pharma Co., Ltd.	Agent de traitement de schizophrénie
MXPA05001707A (es)	2002-08-30	2005-04-19	Pharmacia Corp	Formas de dosificacion farmaceutica solidas que presentan un perfil de liberacion de farmaco reproducible,.
WO2004078173A1 (fr) *	2003-02-05	2004-09-16	Shionogi & Co., Ltd.	Comprime a caracteristiques de dissolution ameliorees
BRPI0414254B8 (pt)	2003-09-12	2021-05-25	Amgen Inc	composição farmacêutica compreendendo hcl de cinacalceto
US8153161B2 (en)	2003-12-09	2012-04-10	Dainippon Sumitomo Pharma Co., Ltd.	Medicament-containing particle and a solid preparation containing the particle
WO2006096439A2 (fr)	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
KR101380088B1 (ko)	2005-05-26	2014-04-10	다이닛본 스미토모 세이야꾸 가부시끼가이샤	약학 조성물

2006
- 2006-05-26 KR KR1020077027270A patent/KR101380088B1/ko active IP Right Grant
- 2006-05-26 SI SI200631567T patent/SI1884242T1/sl unknown
- 2006-05-26 ES ES11181100.6T patent/ES2535478T3/es active Active
- 2006-05-26 EP EP06746900.7A patent/EP1884242B1/fr active Active
- 2006-05-26 BR BR122020005056-0A patent/BR122020005056B1/pt active IP Right Grant
- 2006-05-26 CN CN2010105647842A patent/CN102048734B/zh not_active Expired - Fee Related
- 2006-05-26 DK DK11181100.6T patent/DK2422783T3/en active
- 2006-05-26 PL PL06746900T patent/PL1884242T3/pl unknown
- 2006-05-26 WO PCT/JP2006/310571 patent/WO2006126681A1/fr active Application Filing
- 2006-05-26 MX MX2007014872A patent/MX2007014872A/es active IP Right Grant
- 2006-05-26 JP JP2007517921A patent/JP4733120B2/ja active Active
- 2006-05-26 US US11/919,678 patent/US8729085B2/en active Active
- 2006-05-26 BR BRPI0611409A patent/BRPI0611409B8/pt active IP Right Grant
- 2006-05-26 DK DK06746900.7T patent/DK1884242T3/da active
- 2006-05-26 KR KR1020137027051A patent/KR101552033B1/ko active IP Right Grant
- 2006-05-26 CN CN2006800182234A patent/CN101184489B/zh not_active Expired - Fee Related
- 2006-05-26 AU AU2006250340A patent/AU2006250340C1/en active Active
- 2006-05-26 RU RU2007148997A patent/RU2398586C3/ru not_active Application Discontinuation
- 2006-05-26 ES ES06746900T patent/ES2408687T3/es active Active
- 2006-05-26 PT PT67469007T patent/PT1884242E/pt unknown
- 2006-05-26 CA CA2606510A patent/CA2606510C/fr active Active
- 2006-05-26 EP EP20110181100 patent/EP2422783B1/fr active Active
2008
- 2008-03-03 HK HK08102367.3A patent/HK1108379A1/xx unknown
2011
- 2011-03-18 JP JP2011061211A patent/JP5285105B2/ja active Active
2013
- 2013-05-14 CY CY20131100384T patent/CY1114118T1/el unknown
2014
- 2014-02-18 US US14/183,283 patent/US8883794B2/en active Active
- 2014-09-15 HU HUS1400051C patent/HUS1400051I1/hu unknown
- 2014-09-16 NL NL300690C patent/NL300690I2/nl unknown
- 2014-09-16 FR FR14C0069C patent/FR14C0069I2/fr active Active
- 2014-09-18 LU LU92550C patent/LU92550I2/fr unknown
- 2014-09-18 CY CY2014039C patent/CY2014039I2/el unknown
- 2014-10-10 US US14/512,189 patent/US9555027B2/en active Active
2015
- 2015-06-08 US US14/733,204 patent/US9907794B2/en active Active
2018
- 2018-02-06 US US15/889,893 patent/US20180161322A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUS1400051I1 (hu)	2016-10-28
US9907794B2 (en)	2018-03-06
US20140235651A1 (en)	2014-08-21
NL300690I2 (nl)	2017-11-02
KR101380088B1 (ko)	2014-04-10
US20150056284A1 (en)	2015-02-26
BR122020005056A8 (pt)	2022-11-22
BR122020005056B1 (pt)	2023-01-10
BRPI0611409B1 (pt)	2020-12-29
EP2422783A1 (fr)	2012-02-29
JP4733120B2 (ja)	2011-07-27
EP1884242A1 (fr)	2008-02-06
PT1884242E (pt)	2013-05-21
CN102048734B (zh)	2013-11-20
EP2422783B1 (fr)	2015-04-08
CA2606510C (fr)	2014-07-22
KR101552033B1 (ko)	2015-09-09
CN102048734A (zh)	2011-05-11
HK1108379A1 (en)	2008-05-09
BRPI0611409B8 (pt)	2021-05-25
LU92550I2 (fr)	2015-11-02
AU2006250340B2 (en)	2012-02-09
EP1884242B1 (fr)	2013-04-17
DK2422783T3 (en)	2015-05-11
BR122020005056A2 (fr)	2010-11-23
AU2006250340C1 (en)	2014-06-12
KR20130122019A (ko)	2013-11-06
EP1884242A4 (fr)	2009-07-01
JP2011126915A (ja)	2011-06-30
RU2398586C3 (ru)	2017-10-04
RU2398586C2 (ru)	2010-09-10
FR14C0069I1 (fr)	2014-10-24
US9555027B2 (en)	2017-01-31
JPWO2006126681A1 (ja)	2008-12-25
CN101184489B (zh)	2011-01-19
US20090143404A1 (en)	2009-06-04
US8883794B2 (en)	2014-11-11
US20180161322A1 (en)	2018-06-14
KR20080012306A (ko)	2008-02-11
US20150265611A1 (en)	2015-09-24
CA2606510A1 (fr)	2006-11-30
US8729085B2 (en)	2014-05-20
WO2006126681A1 (fr)	2006-11-30
SI1884242T1 (sl)	2013-07-31
PL1884242T3 (pl)	2013-09-30
MX2007014872A (es)	2008-02-15
BRPI0611409A2 (pt)	2010-11-23
CN101184489A (zh)	2008-05-21
DK1884242T3 (da)	2013-05-06
BRPI0611409A8 (pt)	2015-12-15
ES2535478T3 (es)	2015-05-12
CY1114118T1 (el)	2016-06-22
JP5285105B2 (ja)	2013-09-11
RU2007148997A (ru)	2009-07-10
CY2014039I1 (el)	2016-06-22
CY2014039I2 (el)	2016-06-22
ES2408687T3 (es)	2013-06-21
AU2006250340A1 (en)	2006-11-30

Publication	Publication Date	Title
FR14C0069I2 (fr)	2015-11-20	Composition pharmaceutique comprenant le lurasidone
ITBO20050123A1 (it)	2005-06-06	Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0511900A (pt)	2008-01-22	composições farmacêuticas
NO20075628L (no)	2007-11-05	Farmasøytiske formuleringer
DK1962873T3 (da)	2013-08-26	Farmaceutiske sammensætninger omfattende oxalat-reducerende bakterier
DK1940467T3 (da)	2017-02-13	Lægemiddelsammensætning med langvarig frigivelse
DK1957073T3 (da)	2014-05-12	Lægemiddel
BRPI0715712A2 (pt)	2014-06-24	Composição farmacêutica
BRPI0614205A2 (pt)	2016-11-22	composto, composição farmacêutica, e, uso de composto
BRPI0719393A2 (pt)	2015-03-31	Composição farmacêutica
ATE453384T1 (de)	2010-01-15	Neue dosierformulierung
FR18C1032I2 (fr)	2019-08-09	Anticorps anti-fgf23 et composition pharmaceutique le comprenant
BRPI0716445A2 (pt)	2013-09-17	composiÇço farmacÊutica
BRPI0720234A2 (pt)	2013-12-24	Composição farmacêutica
DK1741339T3 (da)	2014-05-12	Pesticid sammensætning
DK1725218T3 (da)	2014-09-01	Farmaceutisk sammensætning omfattende pimobendan
DK1587478T3 (da)	2013-10-21	Farmaceutisk sammensætning
FR2881643B1 (fr)	2008-12-05	Composition matifiante comprenant de la perlite
DK3072507T3 (da)	2021-02-08	Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
BRPI0615630A2 (pt)	2016-11-16	composição farmacêutica, e, uso de sertindol
MA28603B1 (fr)	2007-05-02	Composition pharmaceutique antimycobacterienne
BRPI0614413A2 (pt)	2016-11-22	composto, e, composição farmacêutica
BRPI0614412A2 (pt)	2016-11-22	composto, e, composição farmacêutica
DK2474528T3 (da)	2014-10-27	Antineoplastiske forbindelser og farmaceutiske kompositioner deraf
DK1906926T3 (da)	2011-01-31	Farmaceutisk sammensætning omfattende 2,3-dihydro-6-nitroimidazo[2,1-b]oxazolderivater